A Corell1,2, L Carstam1,2, A Smits2,3, R Henriksson4,5, A S Jakola1,2,6. 1. Department of Neurosurgery, Sahlgrenska University Hospital, Gothenburg, Sweden. 2. Institute of Neuroscience and Physiology, University of Gothenburg, Sahlgrenska Academy, Gothenburg, Sweden. 3. Department of Neuroscience, Neurology, Uppsala University, Uppsala, Sweden. 4. Regional Cancer Centre Stockholm, Gotland, Sweden. 5. Department of Radiation Science and Oncology, University hospital, Umeå, Sweden. 6. Department of Neurosurgery, St. Olavs University Hospital, Trondheim, Norway.
Abstract
BACKGROUND: Low-grade gliomas (LGG) are slow-growing primary brain tumors that typically affect young adults. Advanced age is widely recognized as a poor prognostic factor in LGG. The impact of age on postoperative outcome in this patient group has not been systemically studied. METHODS: We performed a nationwide register-based study with data from the Swedish Brain Tumor Registry (SBTR) for all adults diagnosed with a supratentorial LGG (WHO grade II astrocytoma, oligoastrocytoma, or oligodendroglioma) during 2005-2015. Patient- and tumor-related characteristics, postoperative complications, and survival were compared between three different age groups (18-39 years, 40-59 years, and ≥60 years). RESULTS: We identified 548 patients; 204 patients (37.2%) aged 18-39 years, 227 patients (41.4%) aged 40-59 years, and 117 patients (21.4%) ≥60 years of age. Unfavorable preoperative prognostic factors (eg, functional status and neurological deficit) were more common with increased age (P < .001). In addition, overall survival was significantly impaired in those 60 years and above (P < .001). We observed a clear dose-response for age with separation of survival curves at 50 years. Biopsy was more common in patients ≥60 years (P < .001). Subgroup analysis of patients with resection revealed a higher amount of postoperative neurological deficits in older patients (P = .029). CONCLUSION: In general, older patients with LGG have several unfavorable prognostic factors compared with younger patients but seem to tolerate surgery in a comparable fashion. However, more neurological deficits were observed following resections in elderly. Our data further support a cutoff at 50 years rather than 40 years for selection of high-risk patients.
BACKGROUND: Low-grade gliomas (LGG) are slow-growing primary brain tumors that typically affect young adults. Advanced age is widely recognized as a poor prognostic factor in LGG. The impact of age on postoperative outcome in this patient group has not been systemically studied. METHODS: We performed a nationwide register-based study with data from the Swedish Brain Tumor Registry (SBTR) for all adults diagnosed with a supratentorial LGG (WHO grade II astrocytoma, oligoastrocytoma, or oligodendroglioma) during 2005-2015. Patient- and tumor-related characteristics, postoperative complications, and survival were compared between three different age groups (18-39 years, 40-59 years, and ≥60 years). RESULTS: We identified 548 patients; 204 patients (37.2%) aged 18-39 years, 227 patients (41.4%) aged 40-59 years, and 117 patients (21.4%) ≥60 years of age. Unfavorable preoperative prognostic factors (eg, functional status and neurological deficit) were more common with increased age (P < .001). In addition, overall survival was significantly impaired in those 60 years and above (P < .001). We observed a clear dose-response for age with separation of survival curves at 50 years. Biopsy was more common in patients ≥60 years (P < .001). Subgroup analysis of patients with resection revealed a higher amount of postoperative neurological deficits in older patients (P = .029). CONCLUSION: In general, older patients with LGG have several unfavorable prognostic factors compared with younger patients but seem to tolerate surgery in a comparable fashion. However, more neurological deficits were observed following resections in elderly. Our data further support a cutoff at 50 years rather than 40 years for selection of high-risk patients.
Authors: Vidya Puthenpura; Maureen E Canavan; Jenny N Poynter; Michael Roth; Farzana D Pashankar; Beth A Jones; Asher M Marks Journal: Pediatr Blood Cancer Date: 2021-03-11 Impact factor: 3.167
Authors: Krissia M Rivera Perla; Nathan J Pertsch; Owen P Leary; Catherine M Garcia; Oliver Y Tang; Steven A Toms; Robert J Weil Journal: Surg Neurol Int Date: 2021-04-08
Authors: Bodil Karoline Ravn Munkvold; Ole Solheim; Jiri Bartek; Alba Corell; Eddie de Dios; Sasha Gulati; Eirik Helseth; Klas Holmgren; Margret Jensdottir; Mina Lundborg; Eduardo Erasmo Mendoza Mireles; Ruby Mahesparan; Øystein Vesterli Tveiten; Peter Milos; Henrietta Nittby Redebrandt; Lars Kjelsberg Pedersen; Jon Ramm-Pettersen; Rickard L Sjöberg; Björn Sjögren; Kristin Sjåvik; Anja Smits; Gregor Tomasevic; Tomás Gómez Vecchio; Einar O Vik-Mo; Maria Zetterling; Øyvind Salvesen; Asgeir S Jakola Journal: Neurooncol Pract Date: 2021-09-04
Authors: Ramin A Morshed; Jacob S Young; Andrew J Gogos; Alexander F Haddad; James T McMahon; Annette M Molinaro; Vivek Sudhakar; Nadeem Al-Adli; Shawn L Hervey-Jumper; Mitchel S Berger Journal: Acta Neurochir (Wien) Date: 2021-12-30 Impact factor: 2.216
Authors: Francesco Latini; Markus Fahlström; Göran Hesselager; Maria Zetterling; Mats Ryttlefors Journal: Cancer Med Date: 2020-06-14 Impact factor: 4.452